Navigation Links
Osteotech's Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
Date:5/2/2008

EATONTOWN, N.J., May 2 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative healing, announced today that its Plexur(R) Technology will be used in a Craniofacial Reconstruction Program led by Dr. Jeffrey Hollinger of Carnegie Mellon University. This program, which was prepared under the auspices of the New Jersey Center for Biomaterials and Dr. Joachim Kohn of Rutgers University, is part of a multi-institutional effort funded by a $42.5 million grant from the Armed Forces Institute of Regenerative Medicine (AFIRM). AFIRM was recently created by the United States Department of Defense to provide funding for the development of regenerative technologies that can be used to treat the most critically injured service members, as well as civilian patients.

The reconstruction program looks to create a new Plexur(R) Biocomposite made of allograft bone fibers or particles and utilizes a novel biodegradable polyurethane to facilitate healing and improve outcomes. This new Plexur(R) Biocomposite will be developed through the collaborative efforts of Dr. Hollinger, Dr. Scott Guelcher at Vanderbilt University, and Osteotech's scientific team. Osteotech has had a long-standing working relationship with Dr. Hollinger and Dr. Guelcher.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased and proud that our Plexur(R) Technology will be used in this research effort at Vanderbilt University and Carnegie Mellon University. The need is great for regenerative solutions to treat serious traumatic injuries to the skull due to wartime injuries. Our Plexur(R) Technology has the potential to offer new solutions in reconstruction of the
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...alif., Nov. 30 BioMarin ...ay that the Food and Drug Administration (FDA) has...ridine (3,4-DAP), amifampridine phosphate, for the...Syndrome (LEMS). 3,4-DAP has previously received ...ber 2009, the Committee for Medicinal Products for...
(Date:11/30/2009)... and COPENHAGEN, Nov. 30 Exiqon A/...hat the Harvard Medical School ICCB-Longwood Scree...croRNA Screening Center of Excellence. ICCB-L sup... associated hospitals and institutions, for high-t...raries. ,, MicroRNAs are a novel class of small...
(Date:11/30/2009)... , AMSTERDAM, November 30 /PRNew...publisher of scientific, medical and technical pro...nch of Embase, its comprehensive biomedical,databa...m more than 7,000,active, peer reviewed journals. ...e advancement of new biomedical,and pharmaceutical...
(Date:11/27/2009)...RHAM, N.C., Nov. 27 Cromoz Inc., l...ter-soluble carbon nanotube-based cancer drug deli... carbon nanotubes, which have functional groups on... drugs, was developed in partnership with the Indi...n nanotubes serves as a drug delivery vehicle with...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...emand for Food, Feed, Fuel, Materials, DES MOINES...CEO Charles O. Holliday, Jr., Executive Vice Presi..., and Group Vice President -- DuPont,Agriculture &... on DuPont,businesses serving the agriculture and ...ng income and demand for biofuels is,driving incre...
...harmaceuticals, Inc. (NYSE: BRL ) today confirmed... initiated a challenge of the patent listed by,War...Chilcott,s Femcon(R),FE (norethindrone and ethinyl...ny believes that it is the first to file an Abbrev...agraph IV certification for Femcon FE. Barr filed...
.... (Other,OTC: BMXSF), is pleased to announce it ha...logies Ltd., for the provision of the design, manu...ery. Pursuant to the engagement,letter, Alcofuel T...onditions of the engagement letter, to design and ...apable of producing 30,000 litres of ethanol,per d...
Other Biology Technology:DuPont Leaders Brief Investors on Agriculture Businesses 2DuPont Leaders Brief Investors on Agriculture Businesses 3Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2
(Date:11/30/2009)...s a colorless and odorless radioactive gas that is...um is a product of uranium decay and is found in t... and groundwater as well as building materials, pl...entration is expressed as the amount of radiation ...cts in a liter of air; thus the units are picocuri...
(Date:11/26/2009)...r their impressive antlers, red deer have been cau...deer,s antlers are much more than decorative. They... duelling. John Currey, from The University of Yor...ties of bone for over half a century and has becom...r through a long-standing collaboration with Tomas...
(Date:11/26/2009)...carried out in eight European countries has shown ... disease pandemic could have a significant role in...g in the open access journal BMC Infectious Disea...l days and weekends/holidays, finding that they we...rom Hasselt and Antwerp University, Belgium, led a...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Tough yet stiff deer antler is materials scientist's dream 2School closure could reduce swine flu transmission by 21 percent 2People Across the Country are Making The Switch 21 53059 1People Across the Country are Making The Switch 21 53059 2Smart for Life 28TM 29 and THINADVENTURE 28TM 29 Sponsor Brandon Flowers Youth Sports Camp 53056 1Smart for Life 28TM 29 and THINADVENTURE 28TM 29 Sponsor Brandon Flowers Youth Sports Camp 53056 2Smart for Life 28TM 29 and THINADVENTURE 28TM 29 Sponsor Brandon Flowers Youth Sports Camp 53056 3ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 13250 1ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 13250 2ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 13250 3
...ed by Rutgers, Samuel Gunderson has developed a no...improvements over existing RNAi approaches. This m...lass of drugs to treat a wide array of diseases. C...m took to specifically target RNA biosynthesis. ,... Nature Biotechnology , published online in the F...
...vance online publication of the journal Nature , ...t viral proteins perform to create the infectious ...ease, say researchers. While the virus they studie... such as herpes and HIV are also known to assemble...its final assault-proof, infectious form. , "The ...
...nerate Energy from Waste Biomass , , ATLANTA, Feb...versified renewable energy company, Global Energy ...ounced the execution of a definitive agreement to ...ndscape materials processor, WoodTech, LLC, and af...expected to occur in mid-February, 2009. , , "We ...
Other Biology News:A new gene silencing platform -- silence is golden 2Scripps scientists create first crystal structure of an intermediate particle in virus assembly 2Scripps scientists create first crystal structure of an intermediate particle in virus assembly 3Global Energy Systems to Acquire WoodTech, LLC, and Affiliated Entities 2Global Energy Systems to Acquire WoodTech, LLC, and Affiliated Entities 3
Calcium Flux Antagonist Chip, 4-Sipper (coated) from Caliper Life Sciences
SYBR Gold nucleic acid gel stain*10,000X concentrate in DMSO* from Molecular Probes (Invitrogen)
Experion RNA StdSens Chips, 10 from Bio-Rad
Experion RNA HighSens Chips, 10 from Bio-Rad
Biology Products: